ArTara Therapeutics, Inc. (TARA)

Last Price:  

Company Description

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. Protara Therapeutics Inc., formerly known as ArTara Therapeutics, is based in NEW YORK, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-14.99M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 2.12
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -118.18%
Return on Assets (Trailing 12 Months) -77.97%
Current Ratio (Most Recent Fiscal Quarter) 9.53
Quick Ratio (Most Recent Fiscal Quarter) 9.53
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $-21.67
Earnings per Share (Most Recent Fiscal Quarter) $-1.22
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) --
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 5.86M
Free Float 3.18M
Market Capitalization $126.36M
Average Volume (Last 20 Days) 0.18M
Beta (Past 60 Months) 0.93
Percentage Held By Insiders (Latest Annual Proxy Report) 45.70%
Percentage Held By Institutions (Latest 13F Reports) 67.69%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%